血管紧张素II作为血管扩张性低血压危重成人首选升压药的一项先导研究:ARAMIS研究
ARAMIS为前瞻性观察性研究,纳入学术型ICU中血管扩张性低血压的危重成人,40例接受血管紧张素II(Ang2)作为首选升压药,与80例匹配对照(去甲肾上腺素、血管加压素、间羟胺、肾上腺素或联合)比较。Ang2组ICU死亡率较低(10%对26%,P=0.04),但28天(18%对29%,P=0.18)和90天(22%对30%,P=0.39)死亡率无显著差异。两组峰值血肌酐、急性肾损伤发生率与分期、连续肾脏替代治疗需求及7天主要不良肾脏事件风险相似;既往暴露于肾素-血管紧张素-醛固酮系统抑制剂的患者中,Ang2组峰值血肌酐较低(交互作用P=0.03),Ang2组肌钙蛋白升高较少(8%对22%,P=0.04)。作者认为Ang2似乎无害,其对ICU生存、肌钙蛋白及RAAS抑制剂患者肾功能的影响需在随机试验中进一步探索。
要点
- 血管扩张性低血压危重成人以Ang2为首选升压药,ICU死亡率10%对传统升压药26%(P=0.04),但28天(18%对29%,P=0.18)和90天(22%对30%,P=0.39)死亡率无显著差异。
- 两组峰值血肌酐(128对126 μmol/L,P=0.81)、急性肾损伤发生率(70%对74%,P=0.66)、连续肾脏替代治疗需求(14%对13%,P=0.84)及7天主要不良肾脏事件(20%对29%,P=0.30)均相似。
- 既往暴露于RAAS抑制剂的患者中,Ang2组峰值血肌酐低于传统升压药组(交互作用P=0.03)。
- Ang2组肌钙蛋白升高较少(8%对22%,P=0.04),血栓栓塞并发症发生率相似。
- 作者认为Ang2在血管扩张性低血压中似乎无害,其对ICU生存、肌钙蛋白及RAAS抑制剂患者肾功能的影响需在随机试验中进一步探索。
适用人群与场景
- 学术型ICU收治的血管扩张性低血压危重成人;40例接受Ang2作为首选升压药,80例匹配对照接受传统升压药(去甲肾上腺素、血管加压素、间羟胺、肾上腺素或联合)。
- 平均年龄63岁,中位急性生理与慢性健康评估III评分65分。
研究设计与关键结果
- 前瞻性观察性研究:40例以Ang2为首选升压药的血管扩张性低血压危重成人,与80例接受传统升压药(去甲肾上腺素、血管加压素、间羟胺、肾上腺素或联合)的匹配对照比较。
- Ang2组ICU死亡率10%对对照组26%(P=0.04);28天死亡率18%对29%(P=0.18),90天死亡率22%对30%(P=0.39),均无显著差异。
- 峰值血肌酐128对126 μmol/L(P=0.81);急性肾损伤发生率70%对74%(P=0.66);连续肾脏替代治疗需求14%对13%(P=0.84);7天主要不良肾脏事件风险20%对29%(P=0.30)。
- 既往暴露于RAAS抑制剂的患者中,Ang2组峰值血肌酐低于传统升压药组(交互作用P=0.03)。
- Ang2组血清肌钙蛋白升高较少(8%对22%,P=0.04);血栓栓塞并发症发生率相似。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究(先导研究),注册号ACTRN12621000281897。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在血管扩张性低血压中以Ang2作为首选升压药似乎无害,但Ang2未降低峰值血肌酐或主要不良肾脏事件,其对ICU生存、血清肌钙蛋白及RAAS抑制剂患者肾功能的影响需在随机试验中进一步探索。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective: The aim of the study is to evaluate the efficacy and safety of using angiotensin II (Ang2) as primary vasopressor for vasodilatory hypotension. Methods: This was a prospective observational study of critically ill adults admitted to an academic intensive care unit (ICU) with vasodilatory hypotension. We treated 40 patients with Ang2 as primary vasopressor and compared them with 80 matched controls who received conventional vasopressors (norepinephrine, vasopressin, metaraminol, epinephrine, or combinations). Results : Mean age was 63 years and median Acute Physiology and Chronic Health Evaluation III score was 65. Ang2 patients had lower ICU mortality (10% vs 26%, P = 0.04); however, their 28- and 90-day mortality was not significantly different (18% vs 29%, P = 0.18; 22% vs 30%, P = 0.39). Peak serum creatinine levels were similar (128 vs 126 μmol/L, P = 0.81), as was the incidence and stage of acute kidney injury (70% vs 74%, P = 0.66), requirement for continuous renal replacement therapy (14% vs 13%, P = 0.84), and risk of major adverse kidney events at 7 days (20% vs 29%, P = 0.30). However, Ang2 patients with prior exposure to renin angiotensin aldosterone system inhibitors had a lower peak serum creatinine ( P = 0.03 for interaction) than conventional vasopressors patients, and serum troponin elevations were less common with Ang2 (8% vs 22%, P = 0.04). The incidence of thromboembolic complications was similar. Conclusions: Primary Ang2 administration in vasodilatory hypotension did not seem harmful compared with conventional vasopressors. Although Ang2 did not decrease peak serum creatinine levels or major adverse kidney events, its effects on intensive care unit survival, serum troponin, and renal function in patients on renin angiotensin aldosterone system inhibitors warrant further exploration in randomized trials (ACTRN12621000281897).
参考来源
- See EJ, Clapham C, Liu J, et al. A PILOT STUDY OF ANGIOTENSIN II AS PRIMARY VASOPRESSOR IN CRITICALLY ILL ADULTS WITH VASODILATORY HYPOTENSION: THE ARAMIS STUDY. Shock. 2023. PMID: 36930693. doi:10.1097/SHK.0000000000002109
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。